These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504 [TBL] [Abstract][Full Text] [Related]
5. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha. Yamagata N; Shimazaki C; Goto H; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Nakagawa M Am J Hematol; 1994 Mar; 45(3):262-4. PubMed ID: 8296801 [TBL] [Abstract][Full Text] [Related]
6. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
7. [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation]. Iino M; Nakajima A; Shindo H Gan To Kagaku Ryoho; 2008 Dec; 35(13):2441-3. PubMed ID: 19098420 [TBL] [Abstract][Full Text] [Related]
8. [Plasma cell leukemia: our experience in 4 cases]. Manso F; Bello JL; Feliu J; García de Bustos J; Losada G; Quevedo E Rev Clin Esp; 1991 Nov; 189(7):328-30. PubMed ID: 1767090 [TBL] [Abstract][Full Text] [Related]
9. [Successful VEP-IFN-alpha therapy in a case of non-secretory plasma cell leukemia (BJ-kappa type)]. Masaki Y; Shimizu S; Takeshita S; Fukutoku M; Yoshioka R; Arai T; Hirose Y; Sugai S; Konda S; Takiguti T Rinsho Ketsueki; 1994 Jun; 35(6):562-8. PubMed ID: 8078191 [TBL] [Abstract][Full Text] [Related]
11. [Clinical and evolutive study of plasma cell leukemia. Apropos of 9 cases]. Panizo Santos C; Cuesta Palomero B; Calasanz Abinzano MJ; Rifón Roca J; Rocha Hernando E Rev Clin Esp; 1997 May; 197(5):341-5. PubMed ID: 9280968 [TBL] [Abstract][Full Text] [Related]
12. [Complete double remission and prolonged survival of a patient diagnosed with plasma cell leukemia]. Sureda A; Pérez de Oteyza J; García Laraña J; Odriozola J Sangre (Barc); 1989 Jun; 34(3):244. PubMed ID: 2762986 [No Abstract] [Full Text] [Related]
13. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia]. Sumi M; Ichikawa N; Shimizu I; Yotsumoto M; Ueno M; Kobayashi H Rinsho Ketsueki; 2007 Jul; 48(7):571-5. PubMed ID: 17695307 [TBL] [Abstract][Full Text] [Related]
14. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Libby E; Candelaria-Quintana D; Moualla H; Abdul-Jaleel M; Rabinowitz I Am J Hematol; 2010 Sep; 85(9):733-4. PubMed ID: 20669178 [No Abstract] [Full Text] [Related]
16. [Multiple myeloma of the IgD-lambda type invading CNS]. Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049 [TBL] [Abstract][Full Text] [Related]